News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
26,040 Results
Type
Article (3957)
Company Profile (4)
Press Release (22078)
Multimedia
Podcasts (31)
Webinars (4)
Section
Business (8982)
Career Advice (41)
Deals (1241)
Drug Delivery (21)
Drug Development (4504)
Employer Resources (12)
FDA (720)
Job Trends (1082)
News (15129)
Policy (1569)
Tag
2027 BioCapital Standard (1)
Academia (81)
Accelerated approval (1)
Adcomms (2)
Allergies (2)
Alliances (2277)
ALS (3)
Alzheimer's disease (38)
Antibody-drug conjugate (ADC) (107)
Approvals (735)
Artificial intelligence (26)
ASCO (66)
Autoimmune disease (13)
Automation (2)
Bankruptcy (9)
Best Places to Work (850)
BIO (1)
BIOSECURE Act (7)
Biosimilars (10)
Biotechnology (1)
Bladder cancer (24)
Brain cancer (11)
Breast cancer (77)
Cancer (572)
Cardiovascular disease (43)
Career advice (44)
Career pathing (2)
CAR-T (11)
CDC (14)
Cell therapy (23)
Cervical cancer (8)
Clinical research (3866)
Collaboration (98)
Company closure (3)
Compensation (7)
Complete response letters (7)
COVID-19 (209)
CRISPR (2)
C-suite (105)
Cystic fibrosis (2)
Data (274)
Depression (4)
Dermatology (1)
Diabetes (7)
Diagnostics (99)
Digital health (1)
Diversity, equity & inclusion (3)
Drug discovery (17)
Drug pricing (51)
Drug shortages (1)
Duchenne muscular dystrophy (6)
Earnings (2327)
Editorial (9)
Employer branding (6)
Employer resources (12)
Events (2581)
Executive appointments (101)
FDA (835)
Funding (59)
Gene editing (9)
Generative AI (3)
Gene therapy (17)
GLP-1 (84)
Government (339)
Grass and pollen (1)
Guidances (8)
Healthcare (484)
Hematology (7)
HIV (16)
Huntington's disease (2)
IgA nephropathy (3)
Immunology and inflammation (34)
Immuno-oncology (22)
Indications (12)
Infectious disease (240)
Inflammatory bowel disease (11)
Inflation Reduction Act (4)
Influenza (1)
Intellectual property (7)
Interviews (2)
IPO (377)
IRA (12)
Job creations (284)
Job search strategy (40)
JPM (9)
Kidney cancer (6)
Labor market (11)
Layoffs (66)
Leadership (2)
Legal (397)
Liver cancer (8)
Longevity (1)
Lung cancer (134)
Lymphoma (15)
Machine learning (2)
Management (4)
Manufacturing (55)
MASH (8)
Medical device (79)
Medtech (79)
Mergers & acquisitions (909)
Metabolic disorders (55)
mRNA (38)
Multiple sclerosis (14)
Neurodegenerative disease (17)
Neuropsychiatric disorders (9)
Neuroscience (86)
NextGen: Class of 2026 (204)
Non-profit (99)
Now hiring (2)
Obesity (37)
Opinion (38)
Ovarian cancer (26)
Pain (6)
Pancreatic cancer (11)
Parkinson's disease (5)
Patents (23)
Patient recruitment (13)
People (4132)
Pharmaceutical (2)
Pharmacy benefit managers (3)
Phase 1 (1107)
Phase 2 (1728)
Phase 3 (1619)
Pipeline (319)
Policy (62)
Postmarket research (206)
Preclinical (281)
Press Release (2)
Prostate cancer (7)
Psychedelics (9)
Radiopharmaceuticals (17)
Rare diseases (36)
Real estate (206)
Recruiting (4)
Regulatory (1120)
Reports (6)
Research institute (75)
Resumes & cover letters (1)
RNA editing (2)
RSV (17)
Schizophrenia (4)
Series A (16)
Series B (9)
Sickle cell disease (3)
Special edition (7)
Spinal muscular atrophy (4)
Sponsored (2)
Startups (217)
Stomach cancer (9)
Supply chain (8)
Tariffs (23)
The Weekly (29)
Vaccines (163)
Venture capital (14)
Weight loss (33)
Women's health (5)
Worklife (1)
Date
Today (6)
Last 7 days (27)
Last 30 days (81)
Last 365 days (1003)
2026 (500)
2025 (1029)
2024 (1236)
2023 (1322)
2022 (2890)
2021 (2705)
2020 (2222)
2019 (1539)
2018 (1204)
2017 (1326)
2016 (1161)
2015 (1306)
2014 (868)
2013 (725)
2012 (794)
2011 (885)
2010 (818)
Location
Africa (65)
Alabama (4)
Alaska (1)
Arizona (3)
Asia (1612)
Australia (404)
California (262)
Canada (99)
China (125)
Colorado (4)
Connecticut (8)
Delaware (14)
Europe (4433)
Florida (69)
Georgia (2)
Illinois (11)
India (1)
Indiana (3)
Japan (67)
Kansas (1)
Kentucky (1)
Maryland (64)
Massachusetts (284)
Michigan (1)
Minnesota (5)
Mississippi (1)
Missouri (3)
Montana (1)
Nevada (2)
New Hampshire (5)
New Jersey (330)
New York (94)
North Carolina (21)
Northern California (140)
Ohio (3)
Oregon (1)
Pennsylvania (31)
Rhode Island (4)
South America (61)
Southern California (96)
Tennessee (1)
Texas (32)
United States (1253)
Utah (8)
Virginia (8)
Washington D.C. (5)
Washington State (32)
West Virginia (1)
Wisconsin (3)
26,040 Results for "merck serono".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Inflammatory bowel disease
Merck posts ‘encouraging’ Phase 3 ulcerative colitis data but Roche challenge looms
Given its intravenous route of administration, Merck’s tulisokibart will likely “need to be meaningfully improved” over Roche’s afimkibart, which can be given subcutaneously, BMO Capital Markets analysts said. Both assets are being tested for ulcerative colitis.
June 23, 2026
·
2 min read
·
Tristan Manalac
M&A
Merck KGaA inks $11B Bio-Techne buyout to expand into cell therapy production
The company is “especially excited” about an immune cell therapy manufacturing technology included in the deal, a Merck KGaA executive said.
June 26, 2026
·
2 min read
·
Nick Paul Taylor
Artificial intelligence
Merck adds to biopharma’s AI agenda with up to $510M+ Protillion pact
Merck will use Protillion Biosciences’ tech to design biologic therapies for therapies across undisclosed indications.
June 17, 2026
·
2 min read
·
Tristan Manalac
Cancer
Merck’s billion-dollar Kelun bet pays off as TROP2 improves survival in endometrial cancer
Merck and Kelun-Biotech’s antibody-drug conjugate significantly improved progression-free and overall survival in a pivotal endometrial cancer study, though the companies have yet to specify when they plan to file for approval.
May 19, 2026
·
2 min read
·
Tristan Manalac
Lung cancer
Merck’s early PD-1/VEGF data competitive in lung cancer, but Summit ‘looms large’
While Merck’s PD-1/VEGF asset appears to match the performance of Summit Therapeutics’ ivonescimab, the pharma’s Phase 1/2 readout in non-small cell lung cancer still leaves analysts with some questions moving into later-stage development.
April 20, 2026
·
2 min read
·
Tristan Manalac
Antibody-drug conjugate (ADC)
ASCO: Merck overshadowed by upstart biotechs but TROP2 plans begin to pay off
Merck may not have had the splashiest presentation at the American Society of Clinical Oncology meeting, but the data show why the Big Pharma remains king of oncology, analysts say.
June 2, 2026
·
4 min read
·
Annalee Armstrong
HIV
Merck, Gilead serve ‘sweet and sour’ spread after HIV win, cancer stumble
While Merck and Gilead Sciences reported back-to-back late-stage victories for their weekly HIV pill, the partners also discontinued a Phase 3 program for their cancer combo after disappointing lung cancer survival data.
June 9, 2026
·
2 min read
·
Tristan Manalac
Kidney cancer
Merck, Eisai’s Keytruda triplet fails to improve survival in kidney cancer
A triplet regimen comprising Merck’s Welireg and PD-1 blockbuster Keytruda and Eisai’s Lenvima flopped in a Phase 3 renal cell carcinoma trial.
April 21, 2026
·
2 min read
·
Tristan Manalac
Cancer
Merck’s PD-1/VEGF data star in stacked lineup of AACR ‘26 data reveals
The Merck update, which will shed light on a $588 million bet to succeed Keytruda, is part of a roster of presentations that could shape the future of ADCs, protein degraders and KRAS-targeted therapies.
April 17, 2026
·
5 min read
·
Nick Paul Taylor
Lung cancer
ASCO: Kelun-Merck ADC shines with differentiated overall survival in first-line lung cancer
Interim overall survival data on a TROP2 ADC from Merck and Chinese partner Kelun-Biotech provide support for the pharma’s big bet on its potential to help navigate Keytruda’s impending loss of exclusivity.
June 1, 2026
·
2 min read
·
Nick Paul Taylor
1 of 2,604
Next
